Viatris Specialty LLC.
Records under this name other than the patents Viatris Specialty LLC. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Back to Viatris Specialty LLC.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,945,620 | Solid Pharmaceutical Compositions Containing Pregabalin Term ended Term ended Nov 2, 2026 · Medium confidence | Term ended | Term ended Nov 2, 2026 | Medium confidence |
| US 9,144,559 | Solid Pharmaceutical Compositions Containing Pregabalin Term ended Term ended Nov 2, 2026 · Medium confidence | Term ended | Term ended Nov 2, 2026 | Medium confidence |
| US 10,022,447 | Solid Pharmaceutical Compositions Containing Pregabalin Term ended Term ended Nov 2, 2026 · Medium confidence | Term ended | Term ended Nov 2, 2026 | Medium confidence |
| US 9,428,455 | Process For Annealing Amorphous Atorvastatin Term ended Ended no later than Sep 11, 2026 · Low confidence | Term ended | Ended no later than Sep 11, 2026 | Low confidence |
| US 7,491,835 | Prodrugs of amino acids with affinity for the α2δ-protein Term ended Term ended Nov 19, 2025 · USPTO record | Term ended | Term ended Nov 19, 2025 | USPTO record |
| US 8,258,315 | Process for forming amorphous atorvastatin Term ended Term ended Oct 12, 2025 · USPTO record | Term ended | Term ended Oct 12, 2025 | USPTO record |
| US 9,056,831 | Process for Forming Amorphous Atorvastatin Term ended Term ended Oct 12, 2025 · Medium confidence | Term ended | Term ended Oct 12, 2025 | Medium confidence |
| US 8,563,750 | Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) Term ended Term ended Aug 4, 2025 · USPTO record | Term ended | Term ended Aug 4, 2025 | USPTO record |
| US 8,895,758 | Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) Term ended Term ended Jul 11, 2025 · Medium confidence | Term ended | Term ended Jul 11, 2025 | Medium confidence |
| US 9,199,932 | Novel Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta, Gamma-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)carbonyl]-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) Term ended Term ended Jul 11, 2025 · Medium confidence | Term ended | Term ended Jul 11, 2025 | Medium confidence |